Lumida
/TGTX
⌘K
TG Therapeutics Inc

TG Therapeutics Inc

TGTX
$54.87USD-0.11%-0.06 today

MARKET CAP

8.4B

P/E (TTM)

84.4x

FWD P/E

31.3x

DAY RANGE

$54 – $56

52W RANGE

$25
$59

AI Summary

Stalk
StalkMedium

TGTX remains in a Stage 2 advancing regime with clear higher-highs and rising EMAs, but a recent Bullish Exhaustion candle, extreme overbought readings, and extended price above the EMAs caution against immediate entry. We prefer to wait for a pullback into the rising 9EMA/21EMA zone near the prior breakout support for a tactical long. Key risk is a break and close below the 9EMA/21EMA, which would signal deeper correction.

  • Q1 2026 U.S. net product revenue $195M (+63% YoY) beat $185–190M guide.
  • Over 25,000 patients prescribed BRIUMVI, expanding real-world installed base.
  • Q1 EPS fell 40% short of estimates, highlighting profit risks.
Full analysis →
Insider Trades4 trades
DateSideTickerInsiderRoleSharesPriceMkt Cap52W High52W LowValue% ChgRuleAI View
Nov 5, 2025SellTGTXMichael S WeissCEO4,668,843$34.04$8.4B-7.47%+117.05%$158.9M-19.63%Stalk
Jan 3, 2025SellTGTXSean A PowerCFO21,358$29.47$8.4B-7.47%+117.05%$629.4K-1.58%Stalk
Jan 3, 2024SellTGTXSean A PowerCFO47,867$16.91$8.4B-7.47%+117.05%$809.4K-7.31%Stalk
Aug 11, 2023BuyTGTXMichael S WeissCEO and President100,000$10.13$8.4B-7.47%+117.05%$1.0M+0.84%Stalk